NASDAQ:FREQ - Frequency Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.50
  • Forecasted Upside: 286.86 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.85
▲ +0.1 (1.48%)

This chart shows the closing price for FREQ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Frequency Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FREQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FREQ

Analyst Price Target is $26.50
▲ +286.86% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Frequency Therapeutics in the last 3 months. The average price target is $26.50, with a high forecast of $56.00 and a low forecast of $9.00. The average price target represents a 286.86% upside from the last price of $6.85.

This chart shows the closing price for FREQ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Frequency Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$12.00 ➝ $9.00High
5/17/2021B. RileyLower Price TargetBuy$35.00 ➝ $21.00Low
3/24/2021B. RileyLower Price TargetBuy$79.00 ➝ $35.00High
3/24/2021OppenheimerLower Price TargetOutperform$68.00 ➝ $20.00Medium
2/11/2021OppenheimerBoost Price TargetOutperform$48.00 ➝ $68.00Low
1/27/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$56.00High
12/22/2020B. RileyInitiated CoverageBuyLow
12/16/2020OppenheimerBoost Price TargetOutperform$36.00 ➝ $48.00High
7/13/2020OppenheimerInitiated CoverageOutperform$36.00High
5/18/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $27.00High
3/27/2020JPMorgan Chase & Co.Boost Price TargetOverweight$26.00 ➝ $28.00High
11/18/2019CowenReiterated RatingBuyMedium
10/28/2019The Goldman Sachs GroupInitiated CoverageBuy$30.00High
10/28/2019JPMorgan Chase & Co.Initiated CoverageOverweight$25.00High
10/28/2019CowenInitiated CoverageOutperformHigh
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 9 very positive mentions
  • 11 positive mentions
  • 13 negative mentions
  • 6 very negative mentions
7/22/2021
  • 6 very positive mentions
  • 13 positive mentions
  • 7 negative mentions
  • 8 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Frequency Therapeutics logo
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $6.85
Low: $6.70
High: $6.88

50 Day Range

MA: $7.36
Low: $6.68
High: $8.34

52 Week Range

Now: $6.85
Low: $6.60
High: $58.37

Volume

85,774 shs

Average Volume

681,758 shs

Market Capitalization

$235.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Frequency Therapeutics?

The following Wall Street research analysts have issued stock ratings on Frequency Therapeutics in the last twelve months: B. Riley, JPMorgan Chase & Co., Oppenheimer Holdings Inc., The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for FREQ.

What is the current price target for Frequency Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Frequency Therapeutics in the last year. Their average twelve-month price target is $26.50, suggesting a possible upside of 286.3%. JPMorgan Chase & Co. has the highest price target set, predicting FREQ will reach $56.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $9.00 for Frequency Therapeutics in the next year.
View the latest price targets for FREQ.

What is the current consensus analyst rating for Frequency Therapeutics?

Frequency Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FREQ will outperform the market and that investors should add to their positions of Frequency Therapeutics.
View the latest ratings for FREQ.

How do I contact Frequency Therapeutics' investor relations team?

Frequency Therapeutics' physical mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The company's listed phone number is 781-315-4600 and its investor relations email address is [email protected] The official website for Frequency Therapeutics is www.frequencytx.com.